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Circulating cell-free DNA (cf-DNA) fragments are small 
double-stranded molecules with a lower molecular 
weight than genomic DNA. High plasma cf-DNA 
concentrations have been documented in critically ill 
patients admitted to the ICU with a good correlation to 
patient outcome [1-8], suggesting this marker has prog-
nostic value. Th e paper by Okkonen and colleagues [1] is 
the ﬁ rst study to assess levels of cf-DNA in plasma as a 
prognostic marker in critically ill patients needing 
mechanical ventilation.
Circulating cf-DNA can be detected in plasma or 
serum samples from healthy individuals at very low 
concentrations, ranging from 2.5 to 27.0  ng/ml in a 
recent meta-analysis [9]. Th e origin and the mechanisms 
whereby these fragments enter the bloodstream are not 
yet fully explained. Apoptosis and active cell release of 
newly synthesized DNA are the main sources of extra-
cellular DNA under normal and pathological conditions 
other than cancer [9]. Results from sequence analysis of 
plasma cf-DNA indicate that the main origin of DNA 
fragments is apoptotic cells and not necrotic cells [10]. In 
addition to apoptosis, all normal and diseased living cells 
may actively release DNA fragments [11]. Th ese frag-
ments can form complexes with glycoprotein and act as 
messengers with signaling functions between cells and 
tissues. Th e elimination of nucleic acids from the blood is 
not dependent on renal clearance [12]. DNA binding to 
cell surface receptors and transport across the plasma 
membrane into many diﬀ erent cells for degradation to 
nucleotides or transportation into the nucleus seem to 
comprise the main mechanism for rapid clearance. 
Plasma nucleases have only a partial role in the removal 
of cf-DNA because these fragments circulate as nucleo-
protein complexes, which protects them from degra da-
tion [9]
Th ree studies have evaluated the potential utility of cf-
DNA measurement in predicting mortality in ICU 
patients [5-7], and another was speciﬁ cally focused on 
septic patients [8]. All of these studies found higher 
plasma cf-DNA concentrations in the patients who died 
compared to survivors, and only one [5] demonstrated 
that DNA could predict the need for mechanical venti la-
tion. Conditions of severe tissue hypoxia leading to a 
need for mechanical ventilation are associated with cell 
apoptosis and the release of DNA into the circulation. 
Okkonen and colleagues [1] performed a large pros-
pective study in 25 Finnish ICUs evaluating plasma 
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apoptotic cells and can refl ect the extent of cellular 
damage. Increased plasma levels of cf-DNA have been 
found in many acute disorders, including septic and 
clinically ill patients, and usually correlate well with 
clinical outcome. Acute respiratory failure, the most 
frequent organ failure in ICU patients, can be related to 
various acute diseases that may cause cell death and 
release of DNA into the bloodstream. In a recent issue 
of Critical Care, Okkonen and colleagues evaluate levels 
of cf-DNA in plasma as a prognostic marker in patients 
needing mechanical ventilation. They report that 
plasma cf-DNA was higher than normal in patients with 
mechanical ventilation, and even higher in patients 
who eventually died compared to survivors. However, 
its usefulness as a death predictor may be limited in 
the heterogeneous group of mechanically ventilated 
patients, probably due to confounding eff ects of co-
morbidities, among other factors.
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cf-DNA concentrations and their prognostic value for 
90-day mortality in 580 patients with acute respiratory 
failure needing mechanical ventilation, 506 of whom 
required an invasive interface. Most of the patients (82%) 
had plasma cf-DNA concentrations higher than the 
upper normal limit of 4,000 GE/ml (26.4 ng/ml) accord-
ing to a meta-analysis. Th e plasma cf-DNA concentration 
at admission was 1.6-fold higher in the 169 patients who 
died than in survivors. A DNA concentration over 16,000 
GE/ml (105.6 ng/ml) was an independent predictor of 
90-day mortality with a moderate discriminative power 
(positive likelihood ratio 1.72; adjusted odds ratio 2.16). 
Surprisingly, cf-DNA concentrations did not diﬀ er 
between the 47 patients fulﬁ lling the diagnostic criteria 
for acute lung injury (ALI)/acute respiratory distress 
syndrome (ARDS) and those who did not, despite the 
assumed higher degree of tissue damage and cell 
apoptosis in the ALI/ARDS patients. Unfortunately, the 
sample size was relatively small for the independent 
eﬀ ect of ALI/ARDS on plasma cf-DNA concentration to 
be robustly analyzed.
Data from Okkonen and colleagues agree with previous 
reports on ICU patients but reﬂ ect diﬀ erences in the 
plasma cf-DNA concentration used in predicting 
mortality. Th is was higher (127 ng/ml) in the study by 
Rhodes and colleagues [6] but lower in two other studies, 
40.3 ng/ml [5] and 61.8 ng/ml [7]. In the series by 
Saukkonen and colleagues (the Finnsepsis Study Group) 
[8], which evaluated 255 patients with severe sepsis or 
septic shock, the best cutoﬀ  value for ICU mortality 
(79.2  ng/ml) was one-fourth lower than in the study by 
Okkonen and colleagues [1]. Methodological diﬀ erences 
at various steps (blood sampling and processing, extrac-
tion methods, measurement principles), while not the 
only cause, are probably the main cause of this discre-
pancy in the values [9]. Th e development of a standard-
ized and widely accepted protocol for cf-DNA analysis is 
warranted [9,11].
Novel methods and biomarkers in critically ill patients 
are necessary. Quantiﬁ cation of circulating cell-free 
mitochondrial and nuclear DNA may provide a platform 
for further investigation [13]. Circulating microRNAs 
(miRNAs), small non-coding RNAs that regulate gene 
expression, play important roles in normal and diseased 
cells. In sepsis, endothelial injury and leukocyte 
activation aﬀ ect the expression level of some miRNAs, 
such as miR-126, which was identiﬁ ed in endothelial 
cells, and some others from leukocytes (miR-146a, 
miR-150, miR-223) [14]. Serum concentrations of miR-
146a and miR-223 were found to be reduced in septic 
patients and they might serve as useful biomarkers for 
sepsis [15]. Th ese and other miRNAs are promising novel 
diagnostic and prognostic tools in ICU patients.
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